CME credits: 1.00

Valid until: 01-03-2025

Claim your CME credit at https://reachmd.com/programs/cme/overcoming-acquired-tki-resistance-with-next-generation-ros1-tki-agents/18161/

This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.